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background: Bioabsorbable arterial stents (BAS) are emerging as a new paradigm for treatment of coronary disease by promoting vascular 
restoration rather than just alleviating the obstruction but caging the vessel segment with a metal stent. We aimed to evaluate mechanical integrity 
and biocompatibility of a novel non-drug eluting, poly-L-lactic acid (PLLA) BAS (Amaranth Medical, Mountain View, CA) featuring unique polymer 
synthesis and processing for improved balance of strength and flexibility.
Methods: Porcine coronary arteries were treated with a novel BAS (n=28) and clinically used BMS (Liberte® Boston Scientific, Natick, MA, n=19) 
as a control under intra vascular ultrasound (IVUS) guidance. Optical coherence tomography (OCT) and histological evaluation was performed at 28 
days (BAS=19, BMS=13) and at 90 days (BAS= 9, BMS= 6).
results: All stents were successfully delivered to their target segments. The acute recoil of BAS was negligible and comparable with BMS. Key 
OCT and histology parameters are in the table. At 90 days the inflammation score for BAS was higher than for BMS but it was moderate and within 
expected range for a degrading PLLA scaffold at this time point.
conclusion: Out to 90 days of follow-up, the novel non-drug eluting BAS showed a favorable mechanical integrity and biocompatibility comparable 
to that of a contemporary BMS. Further long-term investigation of this device is therefore warranted.
Follow up Stent OCT Histology
NIT (mm) %AS NIT (mm)






28 Days BAS 0.28±0.11 31.1±8.7% 0.35±0.1 0.2±0.63 4/4 0.5±0.36
BMS 0.25±0.14 28.5±10.9% 0.27±0.1 0.05±0.13 4/4 0.52±0.38
90 Days BAS 0.29±0.1 33.4±9% 0.44±0.16 1.37±1.2* 4/4 0
BMS 0.25±0.2 27.9±16% 0.32±0.24 0.11±0.17* 4/4 0
*p<0.05; Endothelial Coverage of 4 = Fully covered
